Investing in Project ECHO allowed Health Share to offer continuing education for providers, and many of them now say they enjoy participating in the program, said Christine Bernsten, senior manager of delivery systems transformation for Health Share of Oregon.
Investing in Project ECHO allowed Health Share to offer continuing education for providers, and many of them now say they enjoy participating in the program, said Christine Bernsten, senior manager of delivery systems transformation for Health Share of Oregon.
Transcript (slightly modified)
How did Health Share of Oregon get involved with Project ECHO?
So when CCOs were initially created, we received funding from the Oregon Health Authority to invest in transformative projects, and one of the projects that we initially invested in was called Project ECHO. Because we really saw this as a unique technology and model to link specialists with primary care and be able to provide education in a really accessible way around critical issues for our patient population.
Was there any provider trepidation with getting involved with Project ECHO?
So the providers that participate choose to participate, and they have an incentive of receiving the access to the specialists as well as an hour of free CME for every session that they participate in, so that’s been a nice and easy way to engage people. And I think once people do participate and get involved with this cohort of other providers, they really see the value of the education that they’re getting and they really enjoy participating once they get involved with it.
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
Bimekizumab Poised to Tackle Unmet HS Treatment Needs
October 18th 2024Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get progressively worse over time if it's inadequately treated, explained Amit Garg, MD, founding chair, Department of Dermatology, Northwell Health.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
Bimekizumab Poised to Tackle Unmet HS Treatment Needs
October 18th 2024Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get progressively worse over time if it's inadequately treated, explained Amit Garg, MD, founding chair, Department of Dermatology, Northwell Health.
Read More
2 Commerce Drive
Cranbury, NJ 08512